Department of Medicine, Division of Hematology-Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, U.S.A.
Department of Medicine, Roswell Park Comprehensive Cancer, University of Buffalo, Buffalo, NY, U.S.A.
Anticancer Res. 2020 Feb;40(2):847-855. doi: 10.21873/anticanres.14017.
Fibrolamellar carcinoma (FLC) is a very rare liver tumor. We aimed to retrospectively analyze the clinicopathological factors and treatment modalities affecting overall survival (OS) in FLC. The objective of the study was to identify predictors of survival in FLC.
Using the National Cancer Database, we identified 496 patients diagnosed with FLC between 2004 and 2015. Clinicopathological, treatment, and survival data were collected.
Hepatic resection was performed on 254 (51.2%) patients, liver-directed therapy on 13 (2.6%) patients, and liver transplantation on 15 (3.0%) patients. Median OS by stage were 142.1, 87.2, 32.3, and 14.1 months for stages 1, 2, 3, and 4, respectively. Metastatectomy was not associated with superior median OS (23.4 vs. 10.5 months, p=0.163). Age ≤40, low Charlson-Deyo comorbidity score, early stage and hepatic resection were independently associated with longer OS.
Our study reports current trends in FLC management, and identifies independent predictors of OS.
纤维板层样肝细胞癌（FLC）是一种非常罕见的肝脏肿瘤。我们旨在回顾性分析影响纤维板层样肝细胞癌总生存期（OS）的临床病理因素和治疗方式。本研究的目的是确定影响 FLC 患者生存的预测因素。
我们使用国家癌症数据库，确定了 2004 年至 2015 年间诊断为 FLC 的 496 例患者。收集了临床病理、治疗和生存数据。
254 例（51.2%）患者接受了肝切除术，13 例（2.6%）患者接受了肝定向治疗，15 例（3.0%）患者接受了肝移植。按分期计算，中位 OS 分别为 142.1、87.2、32.3 和 14.1 个月，分期分别为 1、2、3 和 4。转移性切除术与较长的中位 OS 无关（23.4 与 10.5 个月，p=0.163）。年龄≤40 岁、低 Charlson-Deyo 合并症评分、早期分期和肝切除术是与 OS 延长相关的独立因素。
本研究报告了 FLC 管理的当前趋势，并确定了影响 OS 的独立预测因素。
